Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli

Infection

Volumn 36, Issue 1, 2008, Pages 41-45

  Colodner, R ^a   Kometiani, I ^a   Chazan, B ^a,b   Raz, R ^a,c  

^a HAEMEK MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFALEXIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; METRONIDAZOLE; NITROFURANTOIN; OFLOXACIN; PENICILLIN V; QUINOLONE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COMMUNITY ACQUIRED URINARY TRACT INFECTION; CONFIDENCE INTERVAL; DEMENTIA; DEMOGRAPHY; DIABETES MELLITUS; ESCHERICHIA COLI; FEMALE; GERIATRIC PATIENT; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROLITHIASIS; NURSING HOME PATIENT; QUINOLONE RESISTANT ESCHERICHIA COLI; RISK FACTOR; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOLONES; RISK FACTORS; URINARY TRACT INFECTIONS;

EID: 43049155969     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-7083-y     Document Type: Article

References (23)

1. Stamm WE, Norrby RS: Urinary tract infections: disease panorama and challenges. J Infect Dis 2001; 183: S1-S4.
2. Fadda G, Nicoletti G, Schito GC, Tempera G: Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines. J Chemother 2005; 17: 566-567.
3. Foxman B, Brown P: Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 2003; 17: 227-241.
4. Hryniewicz W: Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother 2001; 47: 773-780.
5. Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim- sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002; 34: 1165-1169.
6. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003; 37: 1643-1648.
7. Goettsch W, van Pelt W, Nagelkerke N, et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in The Netherlands. J Antimicrob Chemother 2000; 46: 223-228.
8. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF: Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46: 2540-2545.
9. Ena J, Amador C, Martinez C, Ortiz de la Tabla V: Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol 1995; 153: 117-120.
10. Paterson DL: Resistance in gram-negative bacteria: enterobacteriaceae. Am J Med 2006; 119: S20-S28.
11. Belloc C, Lam DN, Pellerin JL, Beaudeau F, Laval A: Effect of quinolone treatment on selection and persistence of quinoloneresistant Escherichia coli in swine faecal flora. J Appl Microbiol 2005; 99: 954-959.
12. Pertel PE, Haverstock D: Risk factors for a poor outcome after therapy for acute pyelonephritis. BJU Int 2006; 98: 141-147.
13. Piddock LJ: Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 1999; 58: S11-S18.
14. Weigel LM, Steward CD, Tenover FC: GyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother 1998; 42: 2661-2667.
15. Nordmann P, Poirel L: Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother 2005; 56: 463-469.
16. Poirel L, Pitout JD, Calvo L, Rodriguez-Martinez JM, Church D, Nordmann P: In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase. Antimicrob Agents Chemother 2006; 50: 1525-1527.
17. Rock W, Chazan B, Colodner R, Elias M, Raz R: Ten years surveillance of antimicrobial susceptibility of community-acquired uropathogens in northern Israel (1995-2005). Isr Med Assoc J (accepted, July 2007). The 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Munich. March 2007, poster 1135.
18. Lautenbach E, Fishman NO, Bilker WB, Castiglioni A, Metlay JP, Edelstein PH, Strom BL: Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002; 162: 2469-2477.
19. Arslan H, Azap OK, Ergonul O, Timurkaynak F, on behalf of the Urinary Tract Infection Study Group Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005; 56: 914-918.
20. Killgore KM, March KL, Guglielmo BJ: Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004; 38: 1148-1152.
21. Garau J, Xercavins M, Rodriguez-Carballeira M, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999; 43: 2736-2741.
22. Hryniewicz K, Szczypa K, Sulikowska A, et al. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother 2006; 50: 2251-2254.
23. Colodner R, Rock W, Chazan B, Keller N, Guy N, Raz R: Risk factors for the development of extended-spectrum beta-lactamases in non-hospitalized patients. Eur J Clin Microb Infect Dis 2004; 23: 163-167.